Vascular Biogenics analyst ratings
Vascular Biogenics analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/18/2022 | 161.59% | Oppenheimer | → $5.5 | Assumes | → Outperform |
| 04/28/2022 | 137.81% | Chardan Capital | → $5 | Initiates Coverage On | → Buy |
| 06/03/2021 | 232.94% | Roth Capital | $5 → $7 | Maintains | Buy |
| 01/28/2021 | 90.25% | HC Wainwright & Co. | $3 → $4 | Maintains | Buy |
| 04/17/2020 | 42.69% | Oppenheimer | $2 → $3 | Maintains | Outperform |
| 06/27/2019 | -4.88% | Oppenheimer | → $2 | Initiates Coverage On | → Outperform |
| 10/15/2018 | 42.69% | HC Wainwright & Co. | $3 → $3 | Upgrades | Neutral → Buy |
| 03/09/2018 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 03/08/2018 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 07/18/2022 | 161.59% | 奥本海默 | →$5.5 | 假设 | →跑赢大盘 |
| 04/28/2022 | 137.81% | 查尔丹资本 | →$5 | 开始承保 | →购买 |
| 06/03/2021 | 232.94% | 罗斯资本 | $5→$7 | 维护 | 买 |
| 2021年1月28日 | 90.25% | HC Wainwright公司 | $3→$4 | 维护 | 买 |
| 04/17/2020 | 42.69% | 奥本海默 | $2→$3 | 维护 | 跑赢大盘 |
| 2019年06月27日 | -4.88% | 奥本海默 | →$2 | 开始承保 | →跑赢大盘 |
| 2018年10月15日 | 42.69% | HC Wainwright公司 | $3→$3 | 升级 | 中性→购买 |
| 2018年03月09日 | - | 查尔丹资本 | 评级下调 | 购买→中性 | |
| 2018年03月08日 | - | HC Wainwright公司 | 评级下调 | 购买→中性 |
Vascular Biogenics Questions & Answers
血管生物遗传学问答
The latest price target for Vascular Biogenics (NASDAQ: VBLT) was reported by Oppenheimer on July 18, 2022. The analyst firm set a price target for $5.50 expecting VBLT to rise to within 12 months (a possible 161.59% upside). 2 analyst firms have reported ratings in the last year.
奥本海默于2022年7月18日报道了血管生物制药公司(纳斯达克代码：vblt)的最新目标价。这家分析公司将目标价定为5.5美元，预计VBLT将在12个月内升至(可能上涨161.59%)。去年有两家分析公司公布了评级。
The latest analyst rating for Vascular Biogenics (NASDAQ: VBLT) was provided by Oppenheimer, and Vascular Biogenics their outperform rating.
对血管生物制药公司(纳斯达克代码：VBLT)的最新分析师评级是由奥本海默提供的，血管生物制药公司的评级优于他们的评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vascular Biogenics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vascular Biogenics was filed on July 18, 2022 so you should expect the next rating to be made available sometime around July 18, 2023.
分析师在进行了广泛的研究后，才得出股票评级，其中包括查阅公开财务报表，与血管生物基因公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。血管生物遗传公司的上一次评级是在2022年7月18日提交的，所以你应该预计下一次评级将在2023年7月18日左右的某个时候公布。
While ratings are subjective and will change, the latest Vascular Biogenics (VBLT) rating was a with a price target of $0.00 to $5.50. The current price Vascular Biogenics (VBLT) is trading at is $2.10, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的血管生物制药(VBLT)评级为A，目标价在0.00美元至5.50美元之间。血管生物制药(VBLT)目前的交易价格为2.10美元，在分析师的预测范围内。